Prana sinks on Alzheimer's failure; ADDF 'disappointed'
This article was originally published in Scrip
Executive Summary
Prana Biotechnology closed down 71.6% after the Australian company reported that its lead drug candidate PBT2 missed the primary endpoint in a Phase II Alzheimer's disease clinical trial.